This is a standard, non-contentious annual meeting. Traders should note that the proposals are routine and are expected to pass with strong support, as is typical for management-backed votes. No significant market movement is anticipated from this filing.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $68.87entry
- T+1 · 7mo ago +0.19%α +0.84% · $69.00
- T+5 · 7mo ago +10.92%α +10.01% · $76.39
- T+20 · 6mo ago −15.29%α −19.49% · $58.34
- T+60 · 4mo ago +25.82%α +19.04% · $86.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oruka Therapeutics, Inc. (ORKA) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for June 2, 2026. The meeting will address the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and the advisory approval of executive compensation. This is a routine annual shareholder meeting with no activist involvement or contentious issues.
Key Financial Metrics
Key Facts
- The filing is a routine annual proxy statement for the 2026 shareholder meeting.
- Three proposals are on the agenda: election of two Class II directors (Lawrence Klein and Chris Martin), ratification of the independent auditor, and advisory approval of executive compensation.
- The meeting will be held virtually on June 2, 2026.
- The filing was made by the registrant (Oruka Therapeutics, Inc.), indicating it is a standard management proposal.
Financial Impact
No direct financial impact from the filing itself.
Risk Factors
- None identified from the filing itself.
- General market risk associated with the company's performance, which is not addressed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-045169 |
| Document: 0001213900-26-045169-index-headers.html | 0001213900-26-045169 |
| Document: 0001213900-26-045169-index.html | 0001213900-26-045169 |
| Document: 0001213900-26-045169.txt | 0001213900-26-045169 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers